FLT3 and leukemia: Results indicated that CG-806 blocked cells in G1 phase in FLT3-ITD-mutated MOLM14 and MV4–11 leukemia cell lines after 24 h of treatment as determined by BrdU incorporation assay (Fig. 3A, B).